Latest News Releases

PTA-Adhoc: Biofrontera AG: Early repayment of EIB loan

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta028/03.11.2021/14:45) - Biofrontera AG (ISIN: DE0006046113) today decided to prematurely repay the loan raised from the European Investment Bank ("EIB").
Biofrontera AG previously announced that its US subsidiary Biofrontera Inc. had completed a successful capital raise by way of an initial public offering in the USA ("IPO"). As a result of the cash inflow for Biofrontera Inc. as well as its thereby achieved independent access to the US capital market, the liquid funds available to Biofrontera AG are used in part to redeem and repay the loan of nominally 15 million Euro granted by the EIB plus interest and other fees. The total volume of the payment to be made to the EIB amounts to approximately 20 million Euro, whereby the early repayment will reduce future expenses for interest and other fees.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq

[ source: http://www.pressetext.com/news/20211103028 ]

Biofrontera AG – an attractive investment

We are experts in photodynamic therapy. With our innovative products and treatment methods, we make our contribution to skin health and at the same time create value for our investors.

Biofrontera is listed on the Frankfurt Stock Exchange (B8F) and on the NASDAQ Stock Exchange (BFRA) in New York.